Description: C7, Human, mAb WU 4-15

The monoclonal antibody WU 4-15 recognizes C7, one of the components of the terminal complement complex (TCC), also know as the membrane attack complex (MAC). Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 MAC. This complex is assembled from five precursor molecules in the serum, finalized with the polymerization of C9 which accompanies insertion of the complex into the cell membrane causing cellular lysis. C7 occupies an important position in the TCC cascade. C7 undergoes a hydrophilic-amphiphilic transition following activation. It enables the developing MAC to bind directly to target cell membranes. C7 has been shown to exhibit genetic polymorphism. Polymorphonuclear leukocytes represent a major source of C7. The fact that inflammatory cells have the potential to secrete C7 suggests an important role for locally produced complement in the inflammatory process. The monoclonal antibody WU 4-15 identifies an specific allotype of C7: C7 M. 62% of the caucasians is homozygous for C7 M, 31% heterozygous. Antibody Wu 4-15 enables to quantify the contribution of locally synthesized C7 to the inflammatory process and to identify the allotype.

Specifications:

Catalog number Product type Quantity Formulation Application Use Immunogen Isotype Species References Storage and stability Precautions Disease

HM2277

Monoclonal antibodies

100 µg

1 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin.

Flow cytometry, Immuno assays, Immuno fluorescence, Immuno precipitation, Western blot

For flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

Human C7

Mouse IgG1

Human

1. Würzner R et al; Inhibition of terminal complement complex formation and cell lysis by monoclonalantibodies. Complement and Inflammation 1991, 8: 3282. Würzner R et al; Functionally active complement proteins C6 and C7 detected in C6- or C7-deficient individuals. Clin and Exp Immunol 1991, 83: 4303. Würzner R et al; Blood dendritic cells carry terminal complement complexes on their cell surface asdetected by newly developed neoepitope-specific monoclonal antibodies. Immunology 1991, 74:1324. Høgåsen AKM et al; Human polymorphonuclear leukocytes store large amounts of C7 and C6which may be released on stimulation. J of Immunol 1995, 154: 4734v5. Würzner R et al; Complement C7: assessment of in-vivo synthesis after liver transplantationreveals that hepatocytes do not synthesise the majority of human C7. Journal of Immunol 1994,152: 46246. Würzner R et al; Molecular basis of the complement C7 M/N polymorphism: a neutral amino acidsubstitution outside the epitope of the allospecific monoclonal antibody WU 4-15. J. Immunol.1995, 154: 4813

Product should be stored at 4°C. Under recommended storage conditions, product is stable for one year.

For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.

Infectious diseases, Nephrology